Device lead-associated TR
An 82-year-old patient with a pacemaker presents with worsening edema and exertional intolerance. Echo shows moderate-to-severe TR with a lead crossing the tricuspid valve. This case illustrates why device-valve team evaluation — not a single-team recommendation — is the appropriate next step.
Clinical scenario
82-year-old with pacemaker, progressive edema and exertional limitation. Echo: moderate-to-severe TR, pacemaker lead crosses the tricuspid valve, RA/RV enlargement, IVC dilated. What is the evaluation pathway?
Device lead-associated TR with right-heart volume overload. The evaluation pathway requires joint assessment by device specialists and valve experts — not a single-discipline recommendation about the lead or the valve.
Case presentation
An 82-year-old man with a dual-chamber pacemaker (implanted 9 years ago for sick sinus syndrome, pacing-dependent for the past 3 years) presents with progressive lower extremity edema and markedly reduced exercise tolerance over the past 6 months. He denies syncope. Medications include furosemide, which he has been self-increasing.
TTE: A right ventricular pacing lead crosses the tricuspid valve and is seen in contact with the posterior leaflet. TR: moderate-to-severe by qualitative assessment (restricted posterior leaflet motion, malcoaptation adjacent to lead contact). VC 0.70 cm. RA/RV markedly enlarged. IVC 26 mm without respiratory variation. RV systolic function mildly-to-moderately reduced (TAPSE 13 mm). PASP estimated 45 mmHg. Hepatic veins: systolic blunting present.
Echo findings summary
| Parameter | Value | Interpretation |
|---|---|---|
| TR grade (qualitative) | Moderate-to-severe | Significant TR |
| Vena contracta | 0.70 cm | At severe threshold |
| Lead position | Posterior leaflet contact/restriction | Possible mechanical contributor |
| RV size | Markedly enlarged | Significant RV volume overload |
| TAPSE | 13 mm | Mildly-to-moderately reduced |
| IVC | 26 mm, no collapse | Elevated RA pressure |
| Hepatic vein | Systolic blunting | Venous congestion — approaching reversal |
| PASP | 45 mmHg | Moderately elevated |
Tool interpretation
TR Severity Tool: moderate-to-severe TR with significant right-heart impact. VC at the severe threshold, hepatic vein blunting, RV and RA enlargement. May grade as 'likely severe TR' or 'discordant TR' depending on additional severity signals.
TR Intervention Navigator with mechanism = device lead associated: routes to 'device-valve team evaluation.' This is the correct pathway regardless of whether the lead is confirmed as the primary cause.
The core complexity
There are two potential TR contributors in this patient: (1) the lead mechanically restricting the posterior leaflet, and (2) RV dilation and dysfunction from chronic RV pacing-induced cardiomyopathy, which independently causes functional TR. Attributing TR entirely to the lead would miss the latter; attributing TR entirely to RV dysfunction would underestimate the mechanical contribution.
What this tool does not recommend
The TR Intervention Navigator does not recommend lead extraction, lead revision, or lead repositioning. These decisions require specialized assessment of lead integrity, extraction risk, device dependence, and valve anatomy — beyond the scope of any single tool.
Perioperative considerations
If this patient were to undergo noncardiac surgery, the preoperative preparation should include: device interrogation and programming check (pacing mode under anesthesia — VOO or AOO if magnet-sensitive environment), assessment of pacing dependency (rate response behavior, intrinsic rhythm), RV function assessment by TEE intraoperatively for major surgery, and careful volume management given venous congestion and mildly reduced RV function.
Teaching points
- Device lead-associated TR requires multidisciplinary evaluation by both device specialists and valve experts — neither team alone can fully characterize the risk-benefit landscape.
- Lead presence does not prove causality. Functional TR from RV dilation (pacing-induced cardiomyopathy, pre-existing pulmonary hypertension) may coexist with or dominate the clinical picture.
- The TR Intervention Navigator routes device lead mechanism to device-valve team evaluation — not to specific lead or valve management recommendations.
- For noncardiac surgery, device status, pacing dependency, RV function, and venous congestion all require assessment independent of the TR severity question.
- Hepatic vein blunting (approaching reversal) combined with IVC plethora and marked RA/RV enlargement indicates clinically significant venous congestion, even when systolic reversal is not yet present.
Apply this in practice
Use the TR Intervention Navigator — enter mechanism as device lead associated to evaluate the appropriate pathway.
Open TR Intervention Navigator